BlueWillow Biologics, formerly NanoBio Corporation, is an Ann Arbor, Mich.-based clinical-stage biopharmaceutical company led by CEO Dave Peralta. It develops and commercializes intranasal vaccines using its patented NanoVax® technology, an oil-in-water nanoemulsion adjuvant. The NanoVax platform is effective when administered intranasally or intramuscularly and can elicit both mucosal and systemic immunity when applied intranasally. The company is currently developing intranasal vaccines for RSV, pertussis, influenza, anthrax, prophylactic and therapeutic HSV-2, and chlamydia. BlueWillow closed a $10M Series A financing to advance its intranasal technology. It intends to use the funds to continue advancing the intranasal platform toward new vaccines for respiratory and sexually transmitted diseases. NanoBio is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments, and intranasal and intramuscular vaccines derived from its patented NanoStat technology platform. Its lead product candidates include treatments for herpes labialis, onychomycosis, vaginitis, cystic fibrosis and a broad platform of nanoemulsion-based vaccines. The company intends to advance multiple development programs toward commercialization, including topical therapeutics for drug-resistant pathogens and nanoemulsion vaccines for respiratory and sexually transmitted diseases. Recent studies cited by the company highlight the ability of its vaccine technology to elicit both systemic and mucosal immunity at viral entry sites. NanoBio plans to use proceeds from its latest financing to progress programs for herpes labialis, cystic fibrosis and vaccines for RSV and HSV2. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

Total raised

$21M

Funding rounds

2

Latest round

Series A

Latest activity

May 2018